immunosuppressive medication followed for a mean of 2-9 years (range 1 1-4-7 years) only eight became stronger one of whom died. Assessment of weakness (the major impairment), disability, body weight, creatine kinase and the patient's subjective view of their state were essential to obtaining a clear view of progress.
The traditional neurological examination is primarily directed towards establishing an accurate diagnosis. For the motor system, the history, the distribution of weakness between various muscle groups together with changes in tone, coordination and reflexes establish the differential diagnosis. For this application many muscle groups are examined rapidly and annotated using a manual muscle testing system such as the MRC scale,' which subdivides strength into ordinal categories. Functional testing such as sitting from supine, or walking up and down stairs provides essential information for management but its grading is not of primary importance in diagnosis.
By contrast, follow up clinical assessment should include measures of the major impairment caused by the disease (that is, muscle weakness in most cases of muscle disease), a measure of disability such as the ability to sit, stand, walk, swallow and some indication of how this disability is perceived by and affects the patient, that is, handicap. (see  table) . In brief, the examiner holds the dynamometer on the body part and applies sufficient counter force to overcome (and thereby lengthen) the muscle group under test during the patient's best voluntary effort: the force recorded as the examiner overcomes the patient's contraction is taken as the peak force.
When a muscle group is tested against gravity we prefer to add the weight of the limb (weighed on the dynamometer) to the force recorded'0 although difficulties with patient relaxation sometimes make this difficult to measure accurately. In practice an examiner can apply a counter force of up to 250-300 newtons but some muscle groups"' 2 yield higher forces and the technique is therefore inappropriate for monitoring near normal strength in some individuals. Knee extension strength is measured using a special muscle testing chair in which the patient makes a maximum contraction against a fixed strap."3
Handgrip and pinch grip are assessed on a separate dynamometer (MIE Medical Research Ltd). In some patients a test of shoulder abduction fatiguability" is also utilised.
The purpose of measuring strength is to relate it to some estimate of "normal" and to record change over time. We therefore established "guideline" ranges for each of the muscle groups tested in groups of 30 healthy subjects of each sex none of whom undertook regular muscle strengthening exercises (table) .
Functional assessments consisted of a modified version of a scoring system"5 of 0 to 2/ 3 for ventilation, swallowing, use of arms, truncal movements and ambulation: the scores were summed to give a performance score of 0 to 58. In addition, the patient was timed walking 30 m (with one turn) and the number of paces counted: they were also timed up and down 13 stairs and asked to make a vital capacity manoeuvre using a "Vitalograph" spirometer. Swallowing was assessed for the time it takes to drink 150 ml water when this can be done safely. Height and weight are recorded and the patient rated their strength on a 10 cm visual analogue scale ("very weak" to fig 2) This patient, aged 28 years at presentation, had a waddling gait, could only get upstairs holding onto a rail, but could not get up easily from a low chair or sit from supine. Although her CK fell promptly on prednisolone and azathioprine it was some months before she improved in strength. Her CK remained high (1,000-2,000 iu/l) as her strength increased. During prednisolone reduction she hastened the decline in dose covertly and strength was found to have dropped markedly although she did not complain of new symptoms. With increased prednisolone her strength improved by September 1985. As she still complained of significant disabilities, her strength was not in the normal range, and her CK remained elevated she was started on oral low dose cyclophosphamide which, together with a further transient increase in prednisolone dosage, resulted in a further increase in strength and decline in CK.
Although CK remained elevated throughout this patient's illness log CK showed a strong inverse correlation with strength (r = -0 9, p < 0-001). Changes in performance score were small and at the top end of the scale but appeared to correlate with strength so that, for example, ability to sit from supine was reliably predicted by increased strength. The changes in this patient's strength were such that they were all encompassed by MRC grade 4. The patient herself found it helpful to see her progress objectively recorded and this facilitated compliance.
Example 3 (fig 3)
This patient, aged 63 years, was first seen after three months of symptoms when he was profoundly weak, unable to swallow and required positive pressure ventilation. He was grossly wasted with a low CK considering the rapidity of his polymyositis. He responded to prednisolone but this had to be temporarily discontinued because of side effects resulting in a decline in strength in mid 1985 and a rapid rise in CK. Prednisolone was eventually resumed together with low dose oral cyclophosphamide and he improved and was eventually able to walk with one stick. He continued to have mild muscle weakness.
Discussion
While it may be obvious that a patient can improve in days, or even minutes, as in the case of a tensilon test for myasthenia, both clinician and patient can lose the perspective of change in the longer term. We quite regularly notice discrepancies between the subjective analogue score of wellbeing and measures of strength and performance. It is uncommon for patients to insist that they are well when the indicators of disease progress are worsening (for example, fig 1) but the converse is more common. Reports from the laboratory of stability or improvement in condition may be misleading for several reasons. Firstly, a new impairment not covered by testing emerges or progresses (for example, sensory loss in a neuropathy, pain, ataxia, depression). Strength monitoring is inappropriate and misleading if the major disability is due to an impairment other than weakness. A widening disparity between functional performance and strength usually indicates the presence of another impairment as illustrated by the influence of body weight on performance, a point commonly emphasised in the management of wasting diseases.
Secondly, the patient's impression and the laboratory measurements may diverge because muscle groups relevant to the progressive disability are not assessed; particularly common are the failure to monitor bulbar and respiratory muscle function, truncal muscle weakness and hip abduction weakness. Because of the selective nature of muscle involvement in many disorders, it is necessary to identify the sources of disability and the impairment accurately. When reporting muscle strength measurements we pay close attention to serial changes within individual groups and not (initially) to trends in the average values of many muscle groups. When data are reduced for the purposes of a summary chart a misleading graph may arise (for example, one which minimises average strength changes) if disability is the result of very selective muscle involvement. We therefore highlight changes in individual muscle groups if these are perceived as relevant to functional performance whatever the average change is.
Serial measurements of strength and performance allow some validation of this particular (ordinal) performance scale. The scale used is insensitive to changes in strength at the top end but large changes in performance score start to be noted when the average strength in diffuse or proximal myopathy drops to below about 40% of the lower limit of the normal range by gender (fig 3) . Timed tests of certain activities such as walking or swallowing may allow a more precise relationship with strength to be perceived and we are investigating this further.
Summed ordinal scores need caution in interpretation. Although a very wide range of "functional" ordinal scales are available for scoring neurological disabilities we believe that there would be advantages to measuring disabilities where possible in terms of interval units such as time or distance and to relate these to the specific impairments relevant to the disease process in question. Thus walking is commonly abnormal in muscle disease, multiple sclerosis and Parkinson's disease and the degree of disability may be represented by the time taken to walk a specific distance, the number of paces or the stride length: this may be preferred for some purposes to having disease specific disability scales. For clinical trials, notably in Duchenne muscular dystrophy,'6 techniques of strength measurement and/or manual muscle testing are essential. Objective strength measurements appear statistically more powerful than functional testing'7 or manual muscle testing'8 and may easily and routinely be applied to adult neuromuscular disease as a means of clarifying progress.
